Sterling Pharma Solutions and Kivu Bioscience Enter Manufacturing Pact
Sterling Pharma Solutions to produce an antibody-drug conjugate (ADC) candidate for Kivu Bioscience.
Antibody-Drug Conjugate (ADC)
03.01.2025 • News
Innovent Licenses Lung Cancer Therapy Candidate to Roche
Chinese biopharmaceutical company Innovent Biologics announced a collaboration and exclusive license agreement with Roche to advance the development of IBI3009, a novel DLL3-targeted antibody-drug conjugate (ADC) candidate.
15.11.2024 • News
Merck & Co. Licenses Investigational Cancer Drug from LaNova
US drugmaker Merck & Co. (MSD) has entered into a global license agreement to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from Chinese biotechnology company LaNova Medicines.
24.10.2024 • News
Lonza Extends ADC Manufacturing Collaboration with Biopharma Company
Swiss contract development and manufacturing organization (CDMO) Lonza has announced a long-term extension of its collaboration with a key global biopharmaceutical partner for the manufacture of antibody-drug conjugates (ADCs) at commercial scale. The name of the partner was not disclosed.
28.06.2024 • News
Veranova Expands ADC and HPAPI Capabilities in the US
US contract development and manufacturing organization (CDMO) Veranova has initiated an expansion of its antibody-drug conjugate (ADC) and highly potent active pharmaceutical ingredient (HPAPI) development and manufacturing capabilities at its US facility in Devens, Massachusetts.
22.05.2024 • News
Genmab Completes Acquisition of ProfoundBio
Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) and ADC technologies for the treatment of cancers.
22.05.2024 • News
AstraZeneca to Build $1.5 Billion ADC Production Facility in Singapore
In a move to enhance global supply of its antibody drug conjugates (ADCs) portfolio, AstraZeneca intends to build a $1.5 billion facility in Singapore for the manufacturing of ADCs.
04.04.2024 • News
Genmab to Acquire ProfoundBio for $1.8 Billion
Danish drugmaker Genmab has agreed to buy privately-owned US biotechnology company ProfoundBio for $1.8 billion. ProfoundBio develops novel ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors.
A New Standard of Collaboration for the Pharmaceutical Industry
Headquartered in Cramlington, UK, Sterling Pharma Solutions is a contract development and manufacturing organization (CDMO) that provides a range of services to the global biopharmaceutical industry, including active pharmaceutical ingredient (API) development, scale-up and cGMP manufacturing, as well as antibody drug conjugate (ADC) R&D and clinical-scale GMP manufacturing.
